Win or loss? Combination therapy does improve the oncolytic virus therapy to pancreatic cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1475-2867
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Win or loss? Combination therapy does improve the oncolytic virus therapy to pancreatic cancer ; volume:22 ; number:1 ; day:20 ; month:4 ; year:2022 ; pages:1-13 ; date:12.2022
Cancer cell international ; 22, Heft 1 (20.4.2022), 1-13, 12.2022
- Creator
-
Luo, Wenhao
Wang, Yawen
Zhang, Taiping
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12935-022-02583-1
- URN
-
urn:nbn:de:101:1-2022070309124121170178
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:40 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Luo, Wenhao
- Wang, Yawen
- Zhang, Taiping
- SpringerLink (Online service)
Other Objects (12)
Viral Oncolytic Therapy
Development of oncolytic virotherapy: from genetic modification to combination therapy
Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials
Oral systemic therapy: Not all "win-win"
Recent advances of engineered oncolytic viruses-based combination therapy for liver cancer
Autophagy-based therapy for hepatocellular carcinoma: from standard treatments to combination therapy, oncolytic virotherapy, and targeted nanomedicines
Synergistic combination of valproic acid and oncolytic parvovirus H‐1 PV as a potential therapy against cervical and pancreatic carcinomas
Oncolytic vaccinia therapy of squamous cell carcinoma
Enhancing cancer therapy: the integration of oncolytic virus therapy with diverse treatments
Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects
Oncolytic adenoviruses expressing checkpoint inhibitors for cancer therapy
Optimization of oncolytic viral therapy for hepatocellular carcinoma
Viral Oncolytic Therapy
Development of oncolytic virotherapy: from genetic modification to combination therapy
Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials
Oral systemic therapy: Not all "win-win"
Recent advances of engineered oncolytic viruses-based combination therapy for liver cancer
Autophagy-based therapy for hepatocellular carcinoma: from standard treatments to combination therapy, oncolytic virotherapy, and targeted nanomedicines
Synergistic combination of valproic acid and oncolytic parvovirus H‐1 PV as a potential therapy against cervical and pancreatic carcinomas
Oncolytic vaccinia therapy of squamous cell carcinoma
Enhancing cancer therapy: the integration of oncolytic virus therapy with diverse treatments
Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects
Oncolytic adenoviruses expressing checkpoint inhibitors for cancer therapy
Optimization of oncolytic viral therapy for hepatocellular carcinoma
Viral Oncolytic Therapy
Development of oncolytic virotherapy: from genetic modification to combination therapy
Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials
Oral systemic therapy: Not all "win-win"
Recent advances of engineered oncolytic viruses-based combination therapy for liver cancer
Autophagy-based therapy for hepatocellular carcinoma: from standard treatments to combination therapy, oncolytic virotherapy, and targeted nanomedicines
Synergistic combination of valproic acid and oncolytic parvovirus H‐1 PV as a potential therapy against cervical and pancreatic carcinomas
Oncolytic vaccinia therapy of squamous cell carcinoma
Enhancing cancer therapy: the integration of oncolytic virus therapy with diverse treatments
Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects
Oncolytic adenoviruses expressing checkpoint inhibitors for cancer therapy